Economic Evaluation of Transitioning to the 20-Valent Pneumococcal Conjugate Vaccine in the Dutch Paediatric National Immunisation Programme.

Introduction: In 2024, the vaccination strategy against pneumococcal disease in the Dutch paediatric population was changed from the 10-valent pneumococcal conjugate vaccine (PCV) (PCV10) to a 15-valent PCV (PCV15) under a 2 + 1 schedule. We aimed to assess whether switching from PCV15 under a 2 + 1 schedule to 20-valent PCV (PCV20) under a 3 + 1 schedule in the Dutch paediatric national immunisation programme (NIP) would yield economic savings and health benefits.

Methods: A multiple-cohort population model with an annual cycle and 10-year time horizon was adapted for the Dutch population from a societal perspective.

Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.

Background: Alzheimer's disease (AD) is the most common type of dementia, causing progressive decline of memory, thinking, and behavior, impairing daily functioning. Early AD (eAD) includes mild cognitive impairment (MCI) due to AD and mild AD dementia.

Objective: The aim of this study was to investigate symptomatic treatment prevalence and treatment patterns in eAD.